It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

2018

Evotec forms academic BRIDGE 'LAB591’ with Arix Bioscience and Fred Hutchinson Cancer Research Center
Nerina Coppini, 31 May 2018

Combination of one of the premier cancer research centers with a strong company builder and Evotec's drug discovery expertise to create and support new companies focused on therapeutic breakthroughs for patients in the areas of oncology and infectious diseases Expands Evotec's academic ‘BRIDGE’ initiative under EVT INNOVATE Initial term of...

Evotec and Celgene expand IPSC collaboration to include additional cell lines
Nerina Coppini, 29 May 2018

$ 6 M payment to access additional cell lines

Evotec and Celgene enter into strategic oncology partnership
Nerina Coppini, 21 May 2018

Leveraging Evotec's phenotypic screening capabilities and compound libraries with an initial focus on solid tumours Upfront payment of $ 65 M, significant milestone payments and tiered royalties per programme

Evotec reports First Quarter 2018 results and provides Corporate update
Nerina Coppini, 9 May 2018

55% increase in Group revenues Strong underlying operational performance with new business mix after Aptuit acquisition “3X30” outlook for 2018 confirmed Webcast and conference call today at 02.00 pm CEST

Evotec and Carna Biosciences collaborate on INDiGO platform
Nerina Coppini, 8 May 2018

Evotec leverages INDiGO platform to accelerate the development of Carna's programme CB-1763 through to IND filing IND-filing envisaged for first half of 2019 INDiGO, a key value-driving component of Evotec's EVT Execute business segment, accelerates early drug candidates into the clinic by reducing time from nomination to regulatory submission

Evotec expands CRISPR-based technology offering with licence from ERS genomics
Laura Catalina, 2 May 2018

Hamburg, Germany, 02 May 2018:Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene editing, thereby complementing and expanding its...

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard